Executive Chair, City Therapeutics
Appears in 1 story
Guiding the company through its IPO
Cambridge biotech City Therapeutics filed Friday to raise up to $184.7 million in a Nasdaq initial public offering, marketing 9.7 million shares at $17 to $19 each. The company, founded in 2023 by Alnylam Pharmaceuticals' former founding chief executive, develops RNA interference drugs that silence disease-linked genes.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
